Jacobson K A, Siddiqi S M, Olah M E, Ji X D, Melman N, Bellamkonda K, Meshulam Y, Stiles G L, Kim H O
Molecular Recognition Section, National Institute of Diabetes, and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Med Chem. 1995 May 12;38(10):1720-35. doi: 10.1021/jm00010a017.
9-Alkyladenine derivatives and ribose-modified N6-benzyladenosine derivatives were synthesized in an effort to identify selective ligands for the rat A3 adenosine receptor and leads for the development of antagonists. The derivatives contained structural features previously determined to be important for A3 selectivity in adenosine derivatives, such as an N6-(3-iodobenzyl) moiety, and were further substituted at the 2-position with halo, amino, or thio groups. Affinity was determined in radioligand binding assays at rat brain A3 receptors stably expressed in Chinese hamster ovary (CHO) cells, using [125I]AB-MECA (N6-(4-amino-3-iodobenzyl)adenosine-5'-(N-methyluronamide)), and at rat brain A1 and A2a receptors using [3H]-N6-PIA ((R)-N6-phenylisopropyladenosine) and [3H]CGS 21680 (2-[[[4-(2-carboxyethyl)-phenyl]ethyl]amino]-5'- (N-ethylcarbamoyl)adenosine), respectively. A series of N6-(3-iodobenzyl) 2-amino derivatives indicated that a small 2-alkylamino group, e.g., methylamino, was favored at A3 receptors. N6-(3-Iodobenzyl)-9-methyl-2-(methylthio)adenine was 61-fold more potent than the corresponding 2-methoxy ether at A3 receptors and of comparable affinity at A1 and A2a receptors, resulting in a 3-6-fold selectivity for A3 receptors. A pair of chiral N6-(3-iodobenzyl) 9-(2,3-dihydroxypropyl) derivatives showed stereoselectivity, with the R-enantiomer favored at A3 receptors by 5.7-fold. 2-Chloro-9-(beta-D-erythrofuranosyl)-N6-(3-iodobenzyl)adenine had a Ki value at A3 receptors of 0.28 microM. 2-Chloro-9-[2-amino-2,3-dideoxy-beta-D-5-(methylcarbamoyl)- arabinofuranosyl]-N6-(3-iodobenzyl)adenine was moderately selective for A1 and A3 vs A2a receptors. A 3'-deoxy analogue of a highly A3-selective adenosine derivative retained selectivity in binding and was a full agonist in the inhibition of adenylyl cyclase mediated via cloned rat A3 receptors expressed in CHO cells. The 3'-OH and 4'-CH2OH groups of adenosine are not required for activation at A3 receptors. A number of 2',3'-dideoxyadenosines and 9-acyclic-substituted adenines appear to inhibit adenylyl cyclase at the allosteric "P" site.
为了鉴定大鼠A3腺苷受体的选择性配体并寻找拮抗剂开发的先导化合物,合成了9-烷基腺嘌呤衍生物和核糖修饰的N6-苄基腺苷衍生物。这些衍生物具有先前确定对腺苷衍生物中A3选择性很重要的结构特征,如N6-(3-碘苄基)部分,并在2位进一步被卤素、氨基或硫基取代。使用[125I]AB-MECA(N6-(4-氨基-3-碘苄基)腺苷-5'-(N-甲基脲酰胺))在稳定表达于中国仓鼠卵巢(CHO)细胞的大鼠脑A3受体的放射性配体结合试验中测定亲和力,分别使用[3H]-N6-PIA((R)-N6-苯异丙基腺苷)和[3H]CGS 21680(2-[[[4-(2-羧乙基)-苯基]乙基]氨基]-5'-(N-乙基氨基甲酰基)腺苷)在大鼠脑A1和A2a受体中测定亲和力。一系列N6-(3-碘苄基) 2-氨基衍生物表明,在A3受体上小的2-烷基氨基基团,如甲氨基,是有利的。N6-(3-碘苄基)-9-甲基-2-(甲硫基)腺嘌呤在A3受体上的效力比相应的2-甲氧基醚高61倍,在A1和A2a受体上具有相当的亲和力,对A3受体产生3至6倍的选择性。一对手性N6-(3-碘苄基) 9-(2,3-二羟基丙基)衍生物表现出立体选择性,R-对映体在A3受体上受青睐程度高5.7倍。2-氯-9-(β-D-赤藓呋喃糖基)-N6-(3-碘苄基)腺嘌呤在A3受体上的Ki值为0.28 microM。2-氯-9-[2-氨基-2,3-二脱氧-β-D-5-(甲基氨基甲酰)-阿拉伯呋喃糖基]-N6-(3-碘苄基)腺嘌呤对A1和A3受体相对于A2a受体具有中等选择性。一种高度A3选择性的腺苷衍生物的3'-脱氧类似物在结合中保留了选择性,并且在抑制通过CHO细胞中表达的克隆大鼠A3受体介导的腺苷酸环化酶方面是完全激动剂。腺苷的3'-OH和4'-CH2OH基团对于A3受体的激活不是必需的。许多2',3'-二脱氧腺苷和9-无环取代的腺嘌呤似乎在变构“P”位点抑制腺苷酸环化酶。